Telehealth Peptide Prescribing: State-by-State Compliance Guide for 2026

Most peptides are not controlled substances under federal law, which simplifies telehealth prescribing significantly. Unlike Schedule II-V medications, non-controlled peptides prescribed via telemedicine don't require DEA special registration or compliance with the Ryan Haight Act's in-person evaluation requirements. The primary compliance concerns for telehealth peptide prescribing center on state medical board licensing, standard of care requirements, informed consent documentation, and whether the specific peptide can be legally compounded under current FDA regulations.

That said, the landscape is complicated. Practitioners must hold a valid license in the state where the patient is physically located during the consultation. Each state maintains its own telehealth prescribing rules, documentation requirements, and pharmacy board regulations. And the FDA's ongoing review of which peptides qualify for compounding under Section 503A adds another layer of complexity that changes frequently.

This guide covers the federal framework, state-specific requirements for California, Texas, and Ohio, multi-state licensing options, and the documentation standards every practitioner needs to follow.

What Federal Rules Apply to Telehealth Peptide Prescribing?

The regulatory picture depends on whether the peptide in question is classified as a controlled substance.

Non-Controlled Peptides (Most Common)

The majority of therapeutic peptides, including BPC-157, TB-500, sermorelin, CJC-1295, ipamorelin, and GHK-Cu, are not scheduled controlled substances under the Controlled Substances Act. This means:

• The Ryan Haight Act does not apply
• No DEA registration is required for prescribing
• No in-person evaluation mandate exists at the federal level
• Standard telemedicine rules apply (provider licensed in patient's state)

For these peptides, federal requirements focus primarily on whether the substance can be legally compounded under FDA regulations, not on prescribing modality.

When DEA Rules Do Apply

If a peptide is combined with a controlled substance, or if the peptide therapy involves Schedule II-V medications (such as certain compounded formulations containing testosterone or other controlled adjuncts), then DEA telemedicine requirements come into play.

Under the Fourth Temporary Extension issued December 31, 2025, DEA-registered practitioners may prescribe Schedule II-V controlled substances via audio-video telemedicine without an in-person evaluation through December 31, 2026. Audio-only encounters remain permitted for Schedule III-V medications approved for opioid use disorder treatment.

This extension prevents what regulators called a "telemedicine cliff" that could disrupt care for millions of patients who rely on remote prescribing.

The Ryan Haight Act Background

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 normally requires at least one in-person medical evaluation before a practitioner can remotely prescribe controlled substances. The COVID-era flexibilities suspended this requirement, and the extensions have maintained that suspension.

Note that permanent rules remain unfinished. DEA proposed a Special Registration for Telemedicine in January 2025, but the current administration has not finalized the approach. Practitioners should expect the temporary flexibilities to continue coexisting with any future permanent framework.

Which Peptides Can Actually Be Prescribed Through Telehealth?

A valid prescription alone isn't enough. The peptide must also be legally available through compounding.

Understanding FDA 503A Categories

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare peptide formulations only if the bulk drug substance appears on the FDA's approved list or meets specific criteria:

April 2026 Category Changes

On April 15, 2026, the FDA removed 12 peptides from Category 2 after their nominators withdrew the nominations. These include:

• BPC-157
• TB-500 (Thymosin Beta-4)
• MOTS-c
• GHK-Cu (injectable)
• Melanotan II
• Semax
• PEG-MGF

However, removal from Category 2 does not automatically place a peptide in Category 1. Each substance requires individual review by the Pharmacy Compounding Advisory Committee (PCAC) before formal reclassification.

Upcoming PCAC Review Schedule

The PCAC will meet July 23-24, 2026 to discuss adding these peptides to the 503A Bulks List:

July 23, 2026:

• BPC-157-related substances
• KPV-related substances
• TB-500-related substances
• MOTS-c-related substances

July 24, 2026:

• Emideltide (delta sleeping inducing peptide)
• Semax-related substances
• Epitalon-related substances

A second PCAC meeting before February 2027 will review GHK-Cu, Melanotan II, LL-37 (Cathelicidin), Dihexa, and PEG-MGF.

Currently Available Peptides

As of May 2026, peptides that can be legally compounded with a valid prescription include:

• Sermorelin
• CJC-1295 (with and without DAC), pending final Category 1 confirmation
• Ipamorelin
• Tesamorelin
• AOD-9604
• PT-141 (Bremelanotide), some state restrictions apply
• NAD+ formulations

GLP-1 agonists like semaglutide and tirzepatide can be compounded only during FDA-declared shortages.

California Telehealth Prescribing Requirements

California maintains specific rules beyond federal requirements.

Licensing

Physicians providing telehealth services to patients located in California must hold a California medical license. The Medical Board of California does not issue telehealth-only licenses; a full license is required.

New for 2026: Assembly Bill 144, effective January 1, 2026, allows out-of-state practitioners to provide telehealth services if they register with the applicable California regulatory board.

Establishing the Provider-Patient Relationship

Under Business and Professions Code Section 2242, California law prohibits prescribing dangerous drugs "without an appropriate prior examination and a medical indication." For telehealth:

• The examination does not need to be in-person
• It must be sufficient to meet the standard of care for the condition
• Audio-video encounters are standard; audio-only has limitations

Informed Consent Requirements

Business and Professions Code Section 2290.5 mandates specific telehealth consent elements:

1. Explanation of what telehealth involves
2. Limitations of telehealth compared to in-person care
3. Available alternatives to telehealth
4. Patient's right to withdraw consent
5. Emergency protocols
6. Privacy and security information

Document consent in the medical record. Verbal consent is acceptable but must be documented.

DEA Registration

Practitioners prescribing controlled substances (if applicable) to California patients need a separate DEA registration for California. The current fee is $731 for a three-year registration.

Compounding Pharmacy Considerations

California Assembly Bill 1887, effective January 2025, requires all research peptides shipped to California addresses to include a California-specific disclosure statement on the Material Safety Data Sheet (MSDS).

Texas Telehealth Prescribing Requirements

Texas takes a generally less restrictive approach but has specific rules for chronic pain management.

Licensing

A physician licensed in Texas may practice telemedicine within the state. Out-of-state physicians may provide "episodic consultations" without a full Texas license if they:

• Register with the Texas Medical Board (TMB)
• Pay the required registration fee

The TMB proposed rules in September 2024 requiring a full Texas medical license for telehealth providers, with grandfathering for those who held out-of-state telehealth licenses before September 1, 2022.

Chronic Pain and Controlled Substances

TMB rules impose stricter requirements for chronic pain management via telemedicine. Treating chronic pain with scheduled drugs through telemedicine by any means other than audio-video is prohibited unless:

1. The patient is an established chronic pain patient of the physician
2. The prescription is identical to the previous visit's prescription
3. The patient was seen within the last 90 days (in-person or audio-video telemedicine)

Prescription Monitoring

Effective March 1, 2020, providers must check the Texas Prescription Monitoring Program before prescribing:

• Opioids
• Benzodiazepines
• Carisoprodol
• Barbiturates

Standard of Care

Texas Occupations Code, Chapter 111 specifies that health professionals providing telemedicine services are subject to the same standard of care as in-person settings.

Documentation Requirements

Before proceeding with telemedicine, the physician must:

• Obtain informed consent
• Provide HIPAA notice of privacy practices
• Include the required TMB complaint notice

State Peptide Oversight

Texas holds the purchasing institution (not the supplier) liable for ensuring research peptides are used exclusively under approved protocols, per Texas Health and Safety Code Section 431.021(d) as interpreted in a March 2026 advisory memo.

Ohio Telehealth Prescribing Requirements

Ohio finalized new telehealth rules that align with pre-pandemic standards while incorporating pandemic-era lessons.

Schedule II Controlled Substances

Ohio maintains stricter requirements for Schedule II prescribing via telehealth. Physicians must conduct a physical examination during an initial in-person visit before prescribing a Schedule II controlled substance to a new patient.

Exceptions to In-Person Requirements

In-person examination is not required when telehealth services occur in these settings:

When applying an exception, document the specific reason in the patient's medical record.

Technology Requirements

For telemedicine involving controlled substance prescribing to patients without a prior physical examination, communication must use:

• Audio and video equipment
• Two-way, real-time interactive capability

Telephones, fax machines, and email do not qualify.

Recent Legislative Changes

Ohio Revised Code Section 4743.09 was amended by Senate Bill 95 of the 135th General Assembly on April 9, 2025. Controlled substance prescribing through telehealth must conform to federal law exceptions.

Pharmacy Board Requirements

The Ohio State Board of Pharmacy clarified peptide compounding requirements in early 2026:

• All compounded peptides require a valid patient-specific prescription
• The prescriber must be licensed and authorized in Ohio
• Compounding must be patient-specific (no bulk preparation in anticipation)
• Ohio follows federal 503A requirements

How Does Multi-State Licensing Work for Telehealth Providers?

Practitioners offering peptide therapy to patients in multiple states need licenses in each state. The Interstate Medical Licensure Compact (IMLC) simplifies this process.

IMLC Membership

Currently, 43 states plus Washington D.C. and Guam participate in the IMLC. Recent additions include New Jersey, Connecticut, Rhode Island, Delaware, Ohio, and Indiana.

Non-member states include California, New York, Massachusetts, Florida, Hawaii, Alaska, and Arkansas.

How IMLC Works

The Compact streamlines multi-state licensure by allowing eligible physicians to complete one application for licenses in multiple participating states. Key points:

• The IMLC Commission coordinates the process but does not issue licenses
• Each state issues its own license to the physician
• Physicians remain under the jurisdiction of each state's medical board
• The practice of medicine occurs where the patient is located

IMLC Eligibility Requirements

To qualify for IMLC expedited licensure, physicians must:

1. Hold a full, unrestricted medical license in a member state (primary state)
2. Have no disciplinary actions on record
3. Have no criminal history affecting licensure
4. Have completed required graduate medical education
5. Be certified by an ABMS or AOA-recognized specialty board

Cost and Time Savings

IMLC can reduce multi-state licensing costs by $1,000-$3,000 and processing time by 3-6 months compared to individual state applications.

DEA Registration Requirement

Even with IMLC-facilitated medical licenses, practitioners prescribing controlled substances need a separate DEA registration in every state where they prescribe to patients. Current cost: $731 per state for three years.

What Documentation Standards Apply to Telehealth Peptide Prescribing?

Documentation requirements for telehealth mirror in-person standards, with additional elements specific to the remote modality.

Required Documentation Elements

Modality Specification Document the telehealth technology used:

• "Secure interactive audio-video session using [platform name]"
• "Telephone medication management consultation"
• "Asynchronous diagnostic follow-up via patient portal"

Patient Location Record the patient's physical location during the encounter with sufficient detail for audit purposes. This determines which state's laws apply.

Time Documentation Include:

• Total time spent on the encounter
• Start and stop times (some payers require this)
• Time spent on medical decision-making vs. counseling

Others Present Document the name and relationship of anyone on the patient's side of the interaction. Example: "Visit conducted with patient's spouse present for support."

Identity Verification Confirm patient identity to prevent billing fraud and medical identity theft. For new patients, ask them to hold a photo ID near the camera. Document verification in the record.

Informed Consent Documentation

Most states require documented verbal or written consent for telehealth. Annual renewal may be required for Medicaid patients.

Consent documentation should include:

• Patient agreement to receive services via telehealth
• Acknowledgment of telehealth limitations
• Understanding of privacy measures
• Emergency protocols discussed

Prescribing-Specific Requirements

When prescribing via telehealth, document:

• Medical necessity for the prescribed peptide
• Clinical rationale based on documented evaluation
• Discussion of risks, benefits, and alternatives
• Patient's informed consent to the treatment plan
• Any contraindications considered and ruled out

HIPAA Compliance

Telehealth platforms must meet HIPAA requirements:

• End-to-end encryption
• Signed Business Associate Agreements with vendors
• Secure data storage
• Audit trail capabilities

For controlled substance prescribing (when applicable), ensure your EHR or telehealth platform supports Electronic Prescribing for Controlled Substances (EPCS).

Compliance Checklist for Telehealth Peptide Prescribing

Use this checklist before each telehealth peptide consultation:

Licensing Verification

• Hold active, unrestricted medical license in patient's state
• DEA registration in patient's state (if prescribing controlled substances)
• State-specific telehealth registration (if required)

Pre-Encounter Preparation

• Verify patient identity
• Confirm patient's physical location
• Obtain and document informed consent for telehealth
• Review state-specific prescribing requirements

Clinical Documentation

• Document telehealth modality used
• Record patient location
• Log encounter start and stop times
• Note all individuals present during encounter
• Complete standard medical record documentation

Prescribing Compliance

• Verify peptide is on FDA 503A approved list or Category 1
• Check state PDMP (if applicable)
• Document medical necessity and clinical rationale
• Ensure compounding pharmacy compliance with state requirements
• Provide patient education on proper administration

Post-Encounter

• Store records in HIPAA-compliant system
• Maintain audit trail
• Schedule appropriate follow-up

Frequently Asked Questions

Do I need DEA registration to prescribe peptides via telehealth?

For most peptides, no. The majority of therapeutic peptides (BPC-157, TB-500, sermorelin, etc.) are not controlled substances, so DEA registration requirements do not apply to prescribing them. DEA registration matters only if your peptide therapy involves Schedule II-V controlled substances.

Can I prescribe peptides to patients in states where I'm not licensed?

No. You must hold a valid medical license in the state where the patient is physically located during the telehealth encounter. The IMLC can help streamline multi-state licensing if you practice in participating states.

What happens if a patient travels to another state during treatment?

You cannot provide telehealth services to them in the new state unless you hold a license there. Some states allow brief "episodic consultations" for established patients who are temporarily out of state, but prescribing restrictions typically apply.

Are audio-only telehealth visits acceptable for peptide prescribing?

For non-controlled peptides, audio-only may be acceptable depending on state law and whether the encounter meets the applicable standard of care. For controlled substances, audio-video is generally required, with limited exceptions for opioid use disorder treatment.

What's the difference between Category 1 and Category 2 peptides?

Category 1 peptides may be legally compounded by licensed pharmacies with a valid prescription. Category 2 peptides cannot be compounded under any circumstances. As of April 2026, several peptides were removed from Category 2 but are not yet in Category 1; they're awaiting PCAC review and FDA rulemaking.

Key Takeaways

• Most therapeutic peptides are not controlled substances, simplifying telehealth prescribing compared to Schedule II-V medications
• Practitioners must be licensed in the state where the patient is physically located during the encounter
• The IMLC provides expedited multi-state licensing for physicians in 43 participating states
• FDA 503A category status determines whether a peptide can be legally compounded, regardless of prescription validity
• Documentation requirements for telehealth mirror in-person care, with additional modality-specific elements
• State enforcement of peptide prescribing compliance has increased significantly since 2025

Conclusion

Telehealth peptide prescribing operates within a framework that's less burdensome than controlled substance prescribing but still requires careful attention to state licensing, FDA compounding rules, and documentation standards. The April 2026 removal of 12 peptides from Category 2 signals a potential expansion of legally compoundable options, but practitioners should monitor PCAC proceedings and subsequent FDA rulemaking before assuming availability.

For practitioners building a multi-state telehealth practice, the IMLC offers significant time and cost savings for licensing. Regardless of location, maintaining thorough documentation, proper informed consent, and awareness of evolving regulations will remain essential compliance practices.

This content is for informational purposes only and does not constitute legal or medical advice. Consult with healthcare compliance counsel and review current state medical board guidance before establishing telehealth prescribing protocols.

Sources

• HHS & DEA Telemedicine Extension 2026
• DEA Press Release: Fourth Temporary Extension
• Federal Register: Fourth Temporary Extension
• Medical Board of California: Telehealth
• Texas Medical Board: Prescribing and Supervision
• Ohio State Telehealth Laws (CCHP)
• Interstate Medical Licensure Compact
• HHS Telehealth.gov: Licensure Compacts
• FDA PCAC Meeting July 2026
• Frier Levitt: FDA Peptide Update 2026